<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04247126</url>
  </required_header>
  <id_info>
    <org_study_id>SY-5609-101</org_study_id>
    <nct_id>NCT04247126</nct_id>
  </id_info>
  <brief_title>A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1 Study of SY 5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients With Select Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Syros Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Syros Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a dose escalation study and will be the first to administer SY-5609 alone to humans
      with select advanced solid tumors and in combination with Fulvestrant to patients with HR
      positive, HER2-negative breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 23, 2020</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Single Agent Dose Limiting Toxicity</measure>
    <time_frame>Through Study Completion, an average of one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Single Agent Incidence of Adverse Events</measure>
    <time_frame>Through Study Completion, an average of one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Hematologic Lab Values from Baseline</measure>
    <time_frame>Through Study Completion, an average of one year</time_frame>
    <description>Number of Patients with Effects on Laboratory Parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Chemistry Lab Values from Baseline</measure>
    <time_frame>Through Study Completion, an average of one year</time_frame>
    <description>Number of Patients with Effects on Laboratory Parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Coagulation Values from Baseline</measure>
    <time_frame>Through Study Completion, an average of one year</time_frame>
    <description>Number of Patients with Effects on Laboratory Parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Urinalysis Values from Baseline</measure>
    <time_frame>Through Study Completion, an average of one year</time_frame>
    <description>Number of Patients with Effects on Laboratory Parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Electrocardiograms (ECGs)</measure>
    <time_frame>Through Study Completion, an average of one year</time_frame>
    <description>QT Interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body Temperature</measure>
    <time_frame>Through Study Completion, an average of one year</time_frame>
    <description>Celcius</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>Through Study Completion, an average of one year</time_frame>
    <description>mm/hg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>Through Study Completion, an average of one year</time_frame>
    <description>Beats per Minute</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Respiratory Rate</measure>
    <time_frame>Through Study Completion, an average of one year</time_frame>
    <description>Breaths per Minute</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Single Agent Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation phase to explore maximum tolerated dose of SY-5609 given as a single agent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SY-5609 + Fulvestrant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) negative advanced or metastatic breast cancer (BC) that has progressed following prior treatment with a cyclin-dependent kinase (CDK)4/6 inhibitor in combination with hormonal therapy will receive SY-5609 in combination with fulvestrant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SY-5609</intervention_name>
    <description>An oral CDK7 Inhibitor</description>
    <arm_group_label>SY-5609 + Fulvestrant</arm_group_label>
    <arm_group_label>Single Agent Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>estrogen receptor antagonist</description>
    <arm_group_label>SY-5609 + Fulvestrant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years

          2. Advanced Solid Tumors for which standard curative or palliative measures do not exist
             or are no longer effective (Group 1 only).

          3. Postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast
             cancer. Patients must have failed prior treatment with a CDK 4/6 inhibitor in
             combination with hormonal therapy in a previous line of therapy (Group 2 only).

          4. Patients must have at least one (1) measurable lesion by Response Evaluation Criteria
             in Solid Tumors (RECIST) v1.1.

          5. All toxicities (except alopecia) from prior cancer treatments must have resolved to ≤
             Grade 1 before enrollment.

          6. For women of childbearing potential (WCBP): negative serum β human chorionic
             gonadotropin pregnancy test within 1 week before the first dose of SY 5609

          7. Adequate organ and marrow function

          8. Patients must be willing and able to comply with all aspects of the protocol

          9. Patients must provide written informed consent before any study-specific screening
             procedures

        Exclusion Criteria:

          1. Chemotherapy or limited field radiotherapy within two (2) weeks, wide field
             radiotherapy within four (4) weeks, or nitrosoureas or mitomycin C within six (6)
             weeks before entering the study

          2. Major surgery within two (2) weeks before starting the study treatment, or not
             recovered to baseline status from the effects of surgery received &gt; two (2) weeks
             prior

          3. Received any other investigational agents within 4 weeks before enrollment, or &lt; five
             (5) half-lives since completion of previous investigational therapy, whichever is
             shorter

          4. Received previous noncytotoxic, US Food and Drug Administration-approved anticancer
             agent within previous two (2) weeks, or &lt; five (5) half-lives since completion of
             previous therapy, whichever is shorter

          5. Known brain metastases or carcinomatous meningitis

          6. Immunocompromised patients with increased risk of opportunistic infections

          7. Patients with known active or chronic hepatitis B or active hepatitis C infection.
             Patients with a history of hepatitis C virus (HCV) infection who have completed
             curative therapy for HCV at least 12 weeks before Screening and have a documented
             undetectable viral load at Screening are eligible for enrollment.

          8. Baseline QT interval corrected (QTc) with Fridericia's method &gt; 480 ms

               -  NOTE: criterion does not apply to patients with a right or left bundle branch
                  block (QTc interval)

          9. Female patients who are pregnant or breastfeeding

         10. History of clinically significant cardiac disease or clinically relevant uncontrolled
             cardiac risk factors

         11. Uncontrolled intercurrent illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kimberley Caliri</last_name>
    <phone>617-674-9053</phone>
    <email>kcaliri@syros.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tiffany Crowell</last_name>
    <phone>617-674-9069</phone>
    <email>tcrowell@syros.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>START Midwest, LLC</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Skibinski-Preston</last_name>
      <phone>616-954-5552</phone>
      <email>shannon.skibinski@startmidwest.com</email>
    </contact>
    <investigator>
      <last_name>Manish Sharma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana Low</last_name>
      <email>Dana-Low@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Debra Richardson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Scott</last_name>
      <email>Allison.Scott@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Babar Bashir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute - Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacquelyn Spence</last_name>
      <phone>615-340-2830</phone>
      <email>jacquelyn.spence@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Erika Hamilton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Theraputics (START), LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Jimenez, RN, MSN</last_name>
      <phone>210-593-5265</phone>
      <email>isabel.jimenez@startsa.com</email>
    </contact>
    <investigator>
      <last_name>Kyriakos Papadopoulos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 22, 2020</study_first_submitted>
  <study_first_submitted_qc>January 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2020</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

